1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
Wolters, E. E. ; Dodich, A. ; Boccardi, M. ; Corre, J. ; Drzezga, A. ; Hansson, O. LU
; Nordberg, A.
; Frisoni, G. B.
; Garibotto, V.
and Ossenkoppele, R.
LU
(2021)
In European Journal of Nuclear Medicine and Molecular Imaging
48(7).
p.2097-2109
- Contribution to journal › Scientific review
-
Mark
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Bischof, Gérard N. ; Dodich, Alessandra ; Boccardi, Marina ; van Eimeren, Thilo ; Festari, Cristina ; Barthel, Henryk ; Hansson, Oskar LU
; Nordberg, Agneta
; Ossenkoppele, Rik
LU
and Sabri, Osama
, et al.
(2021)
In European Journal of Nuclear Medicine and Molecular Imaging
48(7).
p.2110-2120
- Contribution to journal › Scientific review
-
Mark
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Chiotis, Konstantinos ; Dodich, Alessandra ; Boccardi, Marina ; Festari, Cristina ; Drzezga, Alexander ; Hansson, Oskar LU
; Ossenkoppele, Rik
LU
; Frisoni, Giovanni
; Garibotto, Valentina
and Nordberg, Agneta
(2021)
In European Journal of Nuclear Medicine and Molecular Imaging
48(7).
p.2086-2096
- Contribution to journal › Scientific review